August 5, 2017
Simplify Medical Pty Ltd. announced it has closed $21 million Series B financing, which will be used to support clinical trials of a cervical artificial disc, according to a company press release.
Life Science Partners led the round, along with investment from Sectoral Asset Management and M.H. Carnegie, a returning investor. Simplify Medical will use the new funds to complete two, ongoing pivotal clinical trials of the Simplify Disc in the United States. The trials are enrolling patients and will study the use of the disc for one level of the spine and for two adjacent levels for treatment of cervical degenerative disc disease.